Author(s): Dr Carol Lobo, Assistant Professor; Dr Sumedha Ballal, Associate Professor, Paediatric Dermatologist; Dr Meryl Antony, Associate Professor; Dr John Stephen, Professor, Department of Dermatology, St John’s Medical College, Bangalore, Karnataka, India (2025) Peer reviewed by: Nancy Huang (MBChB), Medical Writer, New Zealand (2025) Previous contributors: Gemma Law, Monash University, Australia; Dr Amanda Oakley, Dermatologist, New Zealand (2015)
Reviewing dermatologist: Dr Ian Coulson Edited by DermNet content department.
Lipoid proteinosis is a rare genodermatosis characterised by the progressivedeposition of amorphoushyaline material in the skin, mucosae, and internal organs. It often presents with hoarseness in early childhood, skin and mucosal changes, and neurological and psychiatric symptoms.
Lipoid proteinosis is also known as Urbach-Wiethe disease or hyalinosis cutis et mucosae.
Lipoid proteinosis is extremely rare, with just over 500 cases reported to date globally. It is inherited in an autosomal recessive pattern; patients often have a positive family history of the disease or are born of a consanguineous union. Disease incidence is equal among men and women.
Most reported cases are of European (Dutch or German) ancestry, though Indian and Chinese cases have also been documented. Although lipoid proteinosis occurs globally, a higher prevalence is noted in the Namaqualand region of the Northern Cape province in South Africa, with all affected patients carrying the same Q276X mutation. This is attributed to a founder effect from a German settler in the mid-17th century.
What causes lipoid proteinosis?
Lipoid proteinosis is an autosomal recessive genodermatosis caused by loss-of-function mutations in the extracellular matrixprotein 1 (ECM1) gene, located on chromosome 1q21. The exact pathogenesis is not yet known, but it is thought that these mutations lead to dysfunction in the binding and production of various extracellular matrix proteins.
ECM1 is an extracellular glycoprotein expressed by various tissues and plays a crucial role in maintaining cutaneoushomeostasis and structural integrity. It is involved in epidermalkeratinocytedifferentiation, structural binding of dermal proteins, angiogenesis, and endochondral bone formation.
What are the clinical features of lipoid proteinosis?
Lipoid proteinosis often presents in early childhood with mucocutaneousmanifestations. A classic early presentation is a weak cry and persistent hoarseness due to vocal cord thickening from hyaline deposition within the laryngealmucosa. Skin thickening occurs and tends to progress over several years. Neurological abnormalities may become evident during early childhood or later in life.
Lipoid proteinosis has a variable phenotype, meaning clinical features differ between affected individuals, even within the same family. While the skin and mucous membranes of the mouth, pharynx, and larynx are commonly affected, hyaline material can infiltrate any part of the body.
Skin lesions result from dermal infiltration and tend to occur in two overlapping stages.
Stage one:
Characterised by recurrentvesiculobullous lesions on the face and extremities, due to skin fragility
These lesions heal slowly with haemorrhagiccrusting and pock-like scarring.
Pock-like scarring
Stage two:
Increased dermal hyaline deposition
Characterised by yellow, waxy papules/plaques that progressively develop and coalesce into diffuse skin thickening
These changes are most apparent on the face, axilla, and scrotum
Moniliform blepharosis, yellowish papules arranged linearly along the eyelid margins and inner canthus, is a classic, pathognomonicsign seen in 50% of patients
Verrucous lesions often develop on extensor surfaces and areas subject to friction eg, elbows, knees, buttocks, axillae, and knuckles.
Pale thickening on the soft palate and loss of dentition (LPR-patient1)
Eyes
Loss of eyebrows and eyelashes (madarosis), abnormally positioned eyelashes (trichiasis), and double eyelashes (distichiasis)
Drusen-like fundal lesions (drusen are yellow deposits under the retina)
Glaucoma and conjunctival nodules
Bilateraluveitis
Corneal ulceration
Retinitis pigmentosa (gradual retinal degeneration, leading to blindness)
Respiratory tract
Infiltration of mucosa along the respiratory tract, including the pharynx and larynx, can lead to:
Weak cry at birth and hoarseness of voice later in life
Breathlessness
Difficulty swallowing.
Central nervous system
Central nervous system involvement is seen in 50-75% of affected individuals. Neuropsychiatric manifestations are highly variable and are thought to primarily occur due to calcifications in the amygdala and temporal lobes.
Symptoms include:
Epilepsy in ~30% of cases (does not always correlate with brain calcifications)
Migraine
Memory deficits and mental retardation
Mood disturbance and social and behavioural changes (eg, anxiety, depression, aggression, paranoia, hallucinations, absence of fear)
Dizziness, ataxia, mild psychomotor retardation, severe generaliseddystonia (muscle spasms and abnormal posture), and transient brachio-facial paralysis.
Neuroimaging with CT/MRI: Bilateral bean-shaped calcifications within the amygdala is considered pathognomonic of lipoid proteinosis; calcifications may also be found in other areas, such as the hippocampus, parahippocampal gyrus, corpus striatum, basalganglia, and pineal gland.
Genetic testing provides a definitive diagnosis for lipoid proteinosis and reveals either homozygous or compound heterozygous loss-of-function mutations of the ECM1 gene.
What is the differential diagnosis for lipoid proteinosis?
Depending on the clinical presentation, the following differentials may be considered:
Due to the rarity of lipoid proteinosis, there are currently no evidence-based guidelines for treatment. Treatment should be individualised according to disease manifestations and the patient’s desire for symptomatic and cosmetic improvement.
A multidisciplinary approach is recommended and may include: a dermatologist, paediatrician, otolaryngologist, neurologist, ophthalmologist, psychiatrist, dentist, and geneticist depending on systemic involvement.
Future effective treatments, such as recombinant ECM1 gene therapy, may be possible.
Specific measures
Mucocutaneous lesions are treated to relieve symptoms and improve cosmetic appearance. Based on case reports or small studies, the following medical and surgical therapies have reported variable success:
Systemic retinoids — case reports describe improvement in cutaneous lesions and vocal hoarseness with long-term acitretin therapy, dosed at 0.5 mg/kg/day
As with other autosomal recessive diseases, genetic carrier testing and reproductive counselling should be offered to couples with a family history of lipoid proteinosis.
What is the outcome for lipoid proteinosis?
Lipoid proteinosis is a chronic, incurable disease that typically runs a slowly progressive and benign course. Prognosis is generally favourable, and life expectancy is normal for most patients, except in cases with respiratory obstruction or central nervous system involvement as these can lead to considerable morbidity or even mortality.
The progressive cutaneous symptoms and persistent vocal hoarseness can have a significant psychosocial impact, affecting work, self-esteem, and overall quality of life.
Bueno-Molina RC, Hernández-Rodríguez J-C, Cabrera-Fuentes R, et al. Advances in treatment for lipoid proteinosis (Urbach–Wiethe disease): a case report and systematic review. Clinical and Experimental Dermatology. 2024;49(6):547-555. doi:10.1093/ced/llae039. Journal
Chan I, Liu L, Hamada T, Sethuraman G, et al. The molecular basis of lipoid proteinosis: mutations in extracellular matrix protein 1. Exp Dermatol. 2007;16(9):881-890. doi:10.1111/j.1600-0625.2007.00608.x. Article
Dyer JA. Chapter 137: Lipoid Proteinosis and Heritable Disorders of Connective Tissue. In: Fitzpatrick’s Dermatology in General Medicine. 8th ed. McGraw-Hill Education; 2012
Gunduz O, Sahiner N, Atasoy P, et al. Acitretin Treatment for Lipoid Proteinosis. Case Rep Dermatol Med. 2012;2012:324506. doi:10.1155/2012/324506. Available here
Hamada T. Lipoid proteinosis. Clin Exp Dermatol. 2002;27(8):624-629. doi:10.1046/j.1365-2230.2002.01143.x. Available here
Kamath SJ, Marthala H, Manapragada B. Ocular manifestations in lipoid proteinosis: A rare clinical entity. Indian J Ophthalmol. 2015;63(10):793-795. doi:10.4103/0301-4738.171517. PubMed
Thornton HB, Nel D, Thornton D, et al. The neuropsychiatry and neuropsychology of lipoid proteinosis. J Neuropsychiatry Clin Neurosci. 2008;20(1):86-92. doi:10.1176/jnp.2008.20.1.86. Journal